1,283 results match your criteria Lithium Nephropathy

End-proximal tubule phosphate concentration increases as GFR falls in humans: measurement by means of a lithium clearance-based methodology.

Nephrol Dial Transplant 2022 May 13. Epub 2022 May 13.

Division of Nephrology, Dialysis and Renal Transplantation, ASST-GOM Niguarda, Milan Italy.

Background: Microscopic nephrocalcinosis secondary to intratubular CaP precipitation is thought to accelerate progression to end-stage renal failure in chronic kidney diseases. In P-loaded uninephrectomized rats intratubular CaP crystal formation and progressive tubular damage occurred when end-proximal tubule P concentration (ePTpc) increased above a threshold level.

Methods: We have calculated ePTpc in humans by urine P and creatinine concentration, with the end-proximal tubule fluid volume calculated either as Li clearance (ePTpc-Li) or as a fixed 0. Read More

View Article and Full-Text PDF

Age-related GSK3β overexpression drives podocyte senescence and glomerular aging.

J Clin Invest 2022 02;132(4)

Division of Nephrology, Department of Medicine and.

As life expectancy continues to increase, clinicians are challenged by age-related renal impairment that involves podocyte senescence and glomerulosclerosis. There is now compelling evidence that lithium has a potent antiaging activity that ameliorates brain aging and increases longevity in Drosophila and Caenorhabditis elegans. As the major molecular target of lithium action and a multitasking protein kinase recently implicated in a variety of renal diseases, glycogen synthase kinase 3β (GSK3β) is overexpressed and hyperactive with age in glomerular podocytes, correlating with functional and histological signs of kidney aging. Read More

View Article and Full-Text PDF
February 2022

Nephrogenic diabetes insipidus: a comprehensive overview.

J Pediatr Endocrinol Metab 2022 Apr 11;35(4):421-434. Epub 2022 Feb 11.

Interdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.

Nephrogenic diabetes insipidus (NDI) is characterized by the inability to concentrate urine that results in polyuria and polydipsia, despite having normal or elevated plasma concentrations of arginine vasopressin (AVP). In this study, we review the clinical aspects and diagnosis of NDI, the various etiologies, current treatment options and potential future developments. NDI has different clinical manifestations and approaches according to the etiology. Read More

View Article and Full-Text PDF

A serum proteomic study of two case-control cohorts identifies novel biomarkers for bipolar disorder.

Transl Psychiatry 2022 02 8;12(1):55. Epub 2022 Feb 8.

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.

We set out to identify novel protein associations with potential as clinically viable biomarkers for bipolar disorder. To this end, we used proximity extension assay to analyze 201 unique proteins in blood serum from two independent cohorts comprising patients with bipolar disorder and healthy controls (total n = 493). We identified 32 proteins significantly associated with bipolar disorder in both case-control cohorts after adjusting for relevant covariates. Read More

View Article and Full-Text PDF
February 2022

MRI-based kidney radiomic analysis during chronic lithium treatment.

Eur J Clin Invest 2022 May 10;52(5):e13756. Epub 2022 Feb 10.

Explorations Fonctionnelles, Physiologie, APHP.Nord Hôpital Bichat, Paris, France.

Background: Lithium therapy during bipolar disorder is associated with an increased risk of chronic kidney disease (CKD) that is slowly progressive and undetectable at early stages. We aimed at identifying kidney image texture features as possible imaging biomarkers of decreased measured glomerular filtration rate (mGFR) using radiomics of T2-weighted magnetic resonance imaging (MRI).

Methods: One hundred and eight patients treated with lithium were evaluated including mGFR and kidney MRI, with T2-weighted sequence single-shot fast spin-echo. Read More

View Article and Full-Text PDF

Myeloid bodies is not an uncommon ultrastructural finding.

Ultrastruct Pathol 2022 Jan 1;46(1):130-138. Epub 2022 Feb 1.

Department of Pathology and Laboratory Medicine, Division of Renal Pathology and Electron Microscopy, University of Rochester Medical Center, Rochester, NY, USA.

The presence of myeloid bodies (MBs) is classically associated with Fabry disease (FD). However, MBs are also identified in patients without clinical evidence of FD. We attempt to further understand the clinicopathologic significance of incidental MBs in those without FD. Read More

View Article and Full-Text PDF
January 2022

Lithium and endocrine dysfunction.

Medicina (B Aires) 2022 ;82(1):130-137

División Endocrinología, Hospital de Clínicas José de San Martín, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.

Lithium carbonate is a commonly prescribed drug for bipolar disorders. In addition to its action on the central nervous system, lithium has systemic effects on multiple organs such as kidney, heart, motor end plate, thyroid and parathyroid glands. It can cause hypothyroidism, hyperthyroidism, goiter and ophthalmopathy by different mechanisms. Read More

View Article and Full-Text PDF
January 2022

Claudin-10a Deficiency Shifts Proximal Tubular Cl Permeability to Cation Selectivity Claudin-2 Redistribution.

J Am Soc Nephrol 2022 04 14;33(4):699-717. Epub 2022 Jan 14.

Clinical Physiology/Division of Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany

Background: The tight junction proteins claudin-2 and claudin-10a form paracellular cation and anion channels, respectively, and are expressed in the proximal tubule. However, the physiologic role of claudin-10a in the kidney has been unclear.

Methods: To investigate the physiologic role of claudin-10a, we generated claudin-10a-deficient mice, confirmed successful knockout by Southern blot, Western blot, and immunofluorescence staining, and analyzed urine and serum of knockout and wild-type animals. Read More

View Article and Full-Text PDF

Nocturia and Chronic Kidney Disease: Systematic Review and Nominal Group Technique Consensus on Primary Care Assessment and Treatment.

Eur Urol Focus 2022 Jan 12;8(1):18-25. Epub 2022 Jan 12.

Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford Kidney Unit, Churchill Hospital, Oxford, UK.

Context: Reduced renal function impairs salt and water homeostasis, which can drive nocturnal or 24-h polyuria. Nocturia can arise early in chronic kidney disease (CKD). Evidence-based recommendations can facilitate management outside nephrology clinics. Read More

View Article and Full-Text PDF
January 2022

[79/f-Somnolence, hypernatremia and acute kidney injury during treatment with lithium : Preparation for the medical specialist examination: part 104].

B Bader

Internist (Berl) 2022 Feb 14;63(Suppl 1):21-26. Epub 2022 Jan 14.

Medizinische Klinik II (Nephrologie und Intensivmedizin), St. Joseph Krankenhaus Berlin-Tempelhof GmbH, Wüsthoffstraße 15, 12101, Berlin, Deutschland.

View Article and Full-Text PDF
February 2022

Atorvastatin does not ameliorate nephrogenic diabetes insipidus induced by lithium or potassium depletion in mice.

Physiol Rep 2021 11;9(21):e15111

Department of Biomedicine, Aarhus University, Aarhus C, Denmark.

Acquired forms of nephrogenic diabetes insipidus (NDI) include lithium (Li)-induced and hypokalemia-induced NDI. Both forms are associated with AQP2 downregulation and collecting duct (CD) cellular remodeling. Statins are cholesterol-lowering drugs appearing to increase AQP2 membrane-translocation and improve urine concentration in other NDI models. Read More

View Article and Full-Text PDF
November 2021

The cascade to a serendipitous discovery of lithium-induced nephrogenic diabetes insipidus.

Asian J Psychiatr 2021 Dec 19;66:102884. Epub 2021 Oct 19.

RCSI-UCD Malaysia University Campus, Penang, Malaysia; Cavan Monaghan Mental Health Service, Carrickmacross County, Ireland.

Lithium therapy is a common treatment for affective disorders and is widely regarded as a lifesaving drug. However, because its elimination is almost wholly unchanged via the kidneys, both acute and long-term adverse effects relating to toxicity may occur, including declining renal function and nephrogenic diabetes insipidus (DI). DI may be difficult to detect and is frequently preceded by dehydration and which, in our patient, was discovered by chance. Read More

View Article and Full-Text PDF
December 2021

An Overlooked Link between IgA Nephropathy and Lithium Toxicity: A Case Report.

Case Rep Nephrol Dial 2021 Sep-Dec;11(3):301-307. Epub 2021 Sep 29.

Department of Nephrology and Hypertension, Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.

Lithium is one of the first-line agents for treating bipolar disorder. Although this agent is highly effective in treating mood disorders, renal toxicity is a frequent side effect. Lithium metabolism is affected by sodium-lithium counter-transporter (SLC-T) in erythrocytes. Read More

View Article and Full-Text PDF
September 2021

Protective effect of metformin on lithium-induced nephrogenic diabetes insipidus: An experimental study in rats.

Adv Clin Exp Med 2021 Nov;30(11):1185-1193

Department of Urology, Faculty of Medicine, Çanakkale Onsekiz Mart University, Turkey.

Background: Lithium is widely used in the treatment of bipolar disorders and may lead to nephrogenic diabetes insipidus (NDI), following long-term treatment. Metformin is considered the preferred initial therapy for patients with type 2 diabetes mellitus (T2D).

Objectives: To investigate the protective effect of metformin on the kidney damage caused by lithium administration. Read More

View Article and Full-Text PDF
November 2021

Renal effects of long-term lithium therapy, revisited.

Hum Psychopharmacol 2022 03 20;37(2):e2812. Epub 2021 Sep 20.

Faculty of Medicine, Department of Internal Diseases, Division of Nephrology, Hacettepe Universitye, Ankara, Turkey.

Objective: The aim of this study was to investigate the effect of lithium treatment on renal function and to determine influencing factors. In addition, the utility of spot urine protein/creatinine ratio in detection of lithium induced nephropathy was also investigated.

Methods: Serum concentrations of lithium, blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR), and urinalysis including protein/creatinine ratio were measured in 375 patients using lithium. Read More

View Article and Full-Text PDF

Genetic background determines renal response to chronic lithium treatment in female mice.

Physiol Genomics 2021 09 11;53(9):406-415. Epub 2021 Aug 11.

The Jackson Laboratory, Bar Harbor, Maine.

Chronic lithium treatment for bipolar disease causes mainly side effects in the kidney. A subset of lithium users develops nephrogenic diabetes insipidus (NDI), a urinary concentrating disorder, and chronic kidney disease (CKD). Age, lithium dose, and duration of treatment are important risk factors, whereas genetic background might also play an important role. Read More

View Article and Full-Text PDF
September 2021

Lithium use in a patient on haemodialysis with bipolar affective disorder and lithium-induced nephropathy.

BMJ Case Rep 2021 Jul 30;14(7). Epub 2021 Jul 30.

Renal and Transplant, Imperial College Healthcare NHS Trust, London, UK

Lithium is an effective mood stabiliser used to treat bipolar affective disorder (BPAD); however, it can also adversely affect the kidneys, causing acute toxic effects, nephrogenic diabetes insipidus, chronic renal dysfunction and end-stage kidney disease (ESKD) in a minority of patients. We describe the case of a man with a 34-year history of BPAD type-1 and a 2-year history of ESKD secondary to lithium-induced nephropathy who experienced a manic relapse. He previously responded well to lithium but, following a deterioration in kidney function, was switched to olanzapine and sodium valproate. Read More

View Article and Full-Text PDF

Animal models for diabetes insipidus.

Handb Clin Neurol 2021 ;181:275-288

Department of Psychobiology, and Mind, Brain and Behavior Research Center, University of Granada, Granada, Spain.

The hormone arginine vasopressin (AVP) is a nonapeptide synthesized by hypothalamic magnocellular nuclei and secreted from the posterior pituitary into the bloodstream. It binds to AVP receptor 2 in the kidney to promote the insertion of aquaporin channels (AQP2) and antidiuretic responses. AVP secretion deficits produce central diabetes insipidus (CDI), while renal insensitivity to the antidiuretic effect of AVP causes nephrogenic diabetes insipidus (NDI). Read More

View Article and Full-Text PDF

Effect of Experimental Fanconi Syndrome on Tubular Reabsorption of Lithium in Rats.

Pharmacology 2021 12;106(7-8):446-450. Epub 2021 May 12.

Department of Pharmaceutics, School of Pharmacy, Aichi Gakuin University, Nagoya, Japan.

Lithium, administered to patients of bipolar disorders, is mainly excreted into urine, and tubular reabsorption at the proximal tubule is involved in the renal handling of lithium. In this study, we examined the renal excretion of lithium in rats with Fanconi syndrome, characterized by defects of transports of various compounds at the proximal tubules, induced by maleic acid. After maleic acid was intravenously injected, mannitol and lithium chloride were infused in turn. Read More

View Article and Full-Text PDF
November 2021

Permissive effect of GSK3β on profibrogenic plasticity of renal tubular cells in progressive chronic kidney disease.

Cell Death Dis 2021 04 30;12(5):432. Epub 2021 Apr 30.

Division of Kidney Disease and Hypertension, Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, RI, 02903, USA.

Renal tubular epithelial cells (TECs) play a key role in renal fibrogenesis. After persistent injuries that are beyond self-healing capacity, TECs will dedifferentiate, undergo growth arrest, convert to profibrogenic phenotypes, and resort to maladaptive plasticity that ultimately results in renal fibrosis. Evidence suggests that glycogen synthase kinase (GSK) 3β is centrally implicated in kidney injury. Read More

View Article and Full-Text PDF

Prediction of individuals at high risk of chronic kidney disease during treatment with lithium for bipolar disorder.

BMC Med 2021 04 28;19(1):99. Epub 2021 Apr 28.

Division of Psychiatry, UCL, London, UK.

Background: Lithium is the most effective treatment in bipolar disorder. Its use is limited by concerns about risk of chronic kidney disease (CKD). We aimed to develop a model to predict risk of CKD following lithium treatment initiation, by identifying individuals with a high-risk trajectory of kidney function. Read More

View Article and Full-Text PDF

Lithium toxicity and the kidney with special focus on nephrotic syndrome associated with the acute kidney injury: A case-based systematic analysis.

J Appl Toxicol 2021 12 2;41(12):1896-1909. Epub 2021 Apr 2.

Department of Nephrology, Transplantology and Internal Diseases, Poznań University of Medical Sciences, Poznań, Poland.

Despite the progress made in treating bipolar and unipolar affective disorders, lithium carbonate is still a common drug in psychiatric practice. Lithium-related renal side effects include nephrogenic diabetes insipidus, chronic tubulointerstitial nephropathy, and acute kidney injury (AKI). Nephrotic syndrome (NS) is an uncommon but severe complication of lithium treatment. Read More

View Article and Full-Text PDF
December 2021

Sub-chronic toxicological evaluation of DC (Apocynaceae) aqueous root extract.

J Complement Integr Med 2021 Apr 1;18(4):753-760. Epub 2021 Apr 1.

Department of Pharmacology, Therapeutics and Toxicology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria.

Objectives: DC (Apocynaceae) has gained wide and extensive applications in herbal medicine in Africa for the treatment of quite a lot of diseases. Owing to the extensive application and the propensity of persistent consumption of this shrub, this research investigates the sub-chronic toxicological effect of aqueous root extract of (SHP) in laboratory animals (rats).

Methods: The rats were allotted into four groups of eight rats each (n=8) and orally treated daily for ninety (90) days with SHP extract at 100, 500 and 1,000 mg/kg and the control group received distilled water (10 mL/kg). Read More

View Article and Full-Text PDF

Determination of finerenone - a novel, selective, nonsteroidal mineralocorticoid receptor antagonist - in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in venous and capillary human plasma.

J Chromatogr B Analyt Technol Biomed Life Sci 2021 May 5;1172:122643. Epub 2021 Mar 5.

Bayer AG, Research & Development, Pharmaceuticals, Translational Medicine, Wuppertal, Germany. Electronic address:

A straightforward and rapid high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay allowing the sensitive and selective quantitation of finerenone (BAY 94-8862) in lithium heparin human plasma is described. Finerenone is a novel, selective, nonsteroidal mineralocorticoid receptor antagonist that is in phase III clinical trials for the treatment of chronic kidney disease. Finerenone quantitation is performed after addition of its stable isotope-labelled internal standard (ISTD) by protein precipitation with acidified acetonitrile followed by HPLC-MS/MS separation and detection. Read More

View Article and Full-Text PDF

An AMPK activator as a therapeutic option for congenital nephrogenic diabetes insipidus.

JCI Insight 2021 04 22;6(8). Epub 2021 Apr 22.

Emory University, Department of Medicine, Renal Division, Atlanta, Georgia, USA.

Nephrogenic diabetes insipidus (NDI) patients produce large amounts of dilute urine. NDI can be congenital, resulting from mutations in the type-2 vasopressin receptor (V2R), or acquired, resulting from medications such as lithium. There are no effective treatment options for NDI. Read More

View Article and Full-Text PDF

Long-term lithium therapy and risk of chronic kidney disease in bipolar disorder: A historical cohort study.

Bipolar Disord 2021 11 11;23(7):715-723. Epub 2021 Mar 11.

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.

Aims: Long-term lithium therapy (LTLT) has been associated with kidney insufficiency in bipolar disorder (BD). We aimed to investigate the risk factors of chronic kidney disease (CKD) development and progression among BD patients receiving LTLT.

Methods: We included adult patients with BD on LTLT (≥1 year) who were enrolled in the Mayo Clinic Bipolar Biobank, Rochester, Minnesota. Read More

View Article and Full-Text PDF
November 2021

An Unexpected Imaging Finding in a CKD Patient on Lithium Therapy.

Kidney360 2021 01 28;2(1):180-181. Epub 2021 Jan 28.

Department of Nephrology, University Hospital Saint-Luc, Brussels, Belgium.

View Article and Full-Text PDF
January 2021

Chronic kidney disease in lithium-treated patients, incidence and rate of decline.

Int J Bipolar Disord 2021 Jan 4;9(1). Epub 2021 Jan 4.

Outpatient Clinic for Bipolar Disorders, Antes Centre for Mental Health Care, Rotterdam, The Netherlands.

Background: Lithium-induced nephropathy is a known long-term complication, sometimes limiting the use of lithium as mood stabilizer. The aim of this study is to establish the incidence of chronic kidney disease and the rate of decline of renal function in patients using lithium and to identify risk factors.

Methods: We selected 1012 patients treated with lithium from the laboratory database of the Antes Centre for Mental Health Care spanning a period from 2000 to 2015. Read More

View Article and Full-Text PDF
January 2021

Lithium, an old friend and a forgotten enemy.

Rev Assoc Med Bras (1992) 2020 Dec;66(12):1625-1627

Department of Internal Medicine, Centro Hospitalar Tondela-Viseu, E.P.E., Viseu, Portugal.

Introduction: Nephrogenic diabetes insipidus (DI) is a polyuric and polydipsic syndrome and can have multiple causing factors.

Case Description: A 69-year-old woman with bipolar disorder medicated with lithium 400mg for 12 years on a daily basis. The patient was admitted, after psychiatric decompensation, with hypernatremia unresponsive to hypotonic iv fluids. Read More

View Article and Full-Text PDF
December 2020

Role of alkali metal oxide type on the degradation and in vivo biocompatibility of soda-lime-borate bioactive glass.

J Biomed Mater Res B Appl Biomater 2021 07 4;109(7):1059-1073. Epub 2020 Dec 4.

Glass Research Department, National Research Centre, Giza, Egypt.

In this work, it is the first time to study the effect of replacing of Na O by a fixed amount of Li O or K O in soda-lime-borate glass on its in vivo biocompatibility. The glass composition was based on xM O-20x Na O20 CaO60 B O , (wt %), where, M OLi O and K O, and consequently, samples encoded BN100, BK50, and BL50. The degradation test was carried out in 0. Read More

View Article and Full-Text PDF